跳至主要内容
临床试验/2023-509027-41-00
2023-509027-41-00已完成1 期

A study to investigate the safety and tolerability of dostarlimab in adult participants with chronic HBV infection on nucleos(t)ide analogue (NA) treatment

Glaxosmithkline Research & Development Limited11 个研究点 分布在 4 个国家目标入组 23 人开始时间: 2024年11月11日最近更新:

试验速览

阶段
1 期
状态
已完成
入组人数
23
试验地点
11

研究概览

简要总结

暂无简介。

入排标准

年龄范围
18 years 至 64 years(18-64 Years)
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Pharmaceutical company
责任方
Principal Investigator
主要研究者

EU GSK Clinical Trials Call Center

Scientific

Glaxosmithkline Research & Development Limited

研究点 (11)

Loading locations...

相似试验

进行中(未招募)
不适用
A study investigating the safety and tolerability of deferiprone in patients with Friedreich's Ataxia - NDpatients affected by Friedreich AtaxiaMedDRA version: 9.1Level: LLTClassification code 10017374Term: Friedreich's ataxia
EUCTR2007-003331-23-ITAPOPHARMA INC., TORONTO, ONTARIO80
已完成
1 期
A programme to develop a skin patch containing two medicines (physostigmine and hyoscine), Study 6: Assessment of blood levels of the two medicines and any associated symptoms in healthy female participants.
ISRCTN15358284Dstl36
已完成
不适用
A study to investigate the safety, tolerability and absorption and elimination of CCX507-B, a new drug for the treatment of patients with inflammatory bowel diseases, in healthy male and female subjects.Crohn's disease.Inflammatory bowel diseases10017969
NL-OMON40895ChemoCentryx, Inc.30
进行中(未招募)
不适用
A study investigating the safety, tolerability and pharmacodynamics of bacterial lipase in patients with cystic fibrosis and pancreatic insufficiencyRandomized, double-blind, placebo-controlled, single period, parallel group desig
EUCTR2006-005180-25-DEordmark Arzneimittel GmbH20
进行中(未招募)
1 期
A Study to Test if TV-46000 is Safe for Maintenance Treatment of SchizophreniaMaintenance treatment of schizophrenia in patients currently treated with oral antipsychoticsMedDRA version: 20.0Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disorders
EUCTR2019-000063-24-FRTeva Branded Pharmaceutical Products R&D, Inc.300